Renalytix plc announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director. Mr. Scannell is a distinguished leader in healthcare innovation, who brings more than 30 years of experience from his time at Stryker. During his time as President and C.O.O., Mr. Scannell was responsible for all commercial businesses and regions globally for Stryker and delivered market-leading results.

Mr. Scannell currently serves as Chair of Insulet Corporation's board of directors and serves on the board of directors for Novocure and Collagen Matrix. Mr. Scannell will be appointed to the board of the company following finalization of the terms of his appointment and the completion of the necessary regulatory due diligence in accordance with the AIM Rules.